1.
Select
A new Bat
Manufact
engineeri
The repor
supported
Consisten
drivers of
knowledg
as one of
countries
environm
The Batte
particular
across the
manufact
occupatio
across the
As an indu
base of hi
engineers
R&D and
challengin
industries
As docum
improve S
global lea
Select fin
 Th
am
re
re
w
t Findings: In
ttelle Techno
turers of Ame
ng, and math
rt also provid
d by PhRMA m
nt with other
f the U.S. econ
ge‐driven glob
the top five p
to nurture po
ent and the e
elle report doc
r concern for
e economy, in
uring compo
ons, which is r
e economy, u
ustry rooted i
igh‐skilled STE
s, mathematic
manufacturin
ng diseases. W
s, U.S. ranking
mented in the
STEM educati
dership in bio
dings from th
here is an inc
mong R&D‐in
equires a bro
eveals that th
wide range of
nnovative Bio
ology Partners
erica (PhRMA
h (STEM) educ
es, for the fir
member com
reports on th
nomy and key
bal economy.
pillars of com
ools of well‐e
evolving need
cuments the
the innovativ
ncluding 810,
nent alone, n
roughly five t
nderscoring t
in science, th
EM workers,
cians, and sci
ng process tha
While the dem
gs on key STE
report, many
ion in the U.S
opharmaceut
he report incl
creasing STEM
ntensive indu
ad range of S
he private sec
STEM jobs re
opharmaceuti
ship Practice
), discusses th
cation, skills,
st time, a rev
panies and th
he state of STE
y to ensuring
A 2011 Wor
petitiveness,
educated wor
ds of the prod
current and p
ve biopharma
000 high‐valu
nearly one‐thi
imes higher t
the importan
e U.S. innova
ranging from
entists with a
at results in n
mand for STE
M measures
y innovative b
S. in order to b
tical R&D.
lude the follo
M skills gap in
ustries such a
STEM skills, tr
tor is already
equired to dev
ical Industry’
report, suppo
he role and im
and training t
view and desc
heir corporat
EM, the study
U.S. global co
rld Economic
noting that “
rkers who are
duction system
projected STE
aceutical indu
ue, high‐wage
ird of the wor
than the aver
ce of STEM s
ative biopharm
m production t
advanced deg
new treatmen
EM workers h
have experie
biopharmaceu
build the 21st
owing:
n the U.S. ver
s the innovat
raining, and
y feeling the s
velop tomorr
s Support of
orted by the P
mportance of
to U.S. econo
cription of the
e foundation
y finds that ST
ompetitivene
Forum report
“today’s globa
e able to adap
m.”
EM talent gap
ustry as it sup
e direct jobs.
rkforce is em
age share of
kills to this R&
maceutical in
technicians w
grees, who ar
nts and cures
as increased
enced marked
utical compan
t
Century STE
rsus other co
tive biopharm
education at
shortage of ST
row’s new tre
STEM Educat
Pharmaceutic
f science, tech
omic growth a
e broad range
s in the U.S.
TEM workers
ess in an incre
t cited well‐e
alizing econo
pt rapidly to t
p in the U.S. w
ports over 3.4
In the indust
ployed in STE
STEM‐related
&D‐intensive
dustry is criti
with high scho
re involved in
against our m
for this and o
d declines in r
nies have tak
M workforce
untries creat
maceutical in
t all degree le
TEM talent an
eatments and
tion in the U.
cal Research
hnology,
and sustainab
e of STEM eff
s are critical
easingly
educated wor
omy requires
their changing
which is of
4 million jobs
try’s
EM‐related
d employmen
industry.
ically tied to i
ool degrees to
every stage o
most costly a
other high‐R&
recent years.
ken action to
and maintain
ting concern
ndustry, which
evels. The rep
nd describes t
cures here in
.S
and
bility.
forts
kers
g
s
nt
ts
o
of the
nd
&D
n U.S.
h
port
the
n the

2. U.S. It also notes U.S. STEM education funding is declining at a time when other countries are
increasingly investing in STEM education in order to attract innovative R&D industries.
 Innovative biopharmaceutical companies and their corporate foundations are making
significant contributions to U.S. STEM education through a broad range of local, state, and
national level programs and initiatives aimed at elementary through post‐secondary
education. Over the past five years, the 24 PhRMA member companies voluntarily reporting,
funded more than 90 individual initiatives focused on students and/or teachers in STEM‐related
fields, the majority of which have been active within the last year.
 Over the last five years, PhRMA member company STEM programs have impacted over 1.6
million students and 17,500 teachers across the U.S. On a current annual basis, about 500,000
students and 8,000 teachers participate in STEM education programs supported by PhRMA
members.
 PhRMA member company programs are impacting students and teachers across the country,
through 14 national‐level programs that range from funding third‐party STEM education
initiatives, to supporting scholarships in STEM‐related fields, to sponsoring STEM‐related
competitions to foster interest in STEM fields. Additional STEM activities are being supported in
26 states, Washington D.C., and Puerto Rico, with a larger concentration of activities in states
with a deeper industry presence.
 In total, the 24 PhRMA member companies and their foundations responding have invested
over $100 million in STEM education related initiatives since 2008, including awarding nearly
600 individual STEM education related grants. In 2012 alone, these PhRMA member companies
invested over $10 million in supporting STEM education efforts.
 In addition to financial contributions, PhRMA member companies are also making significant
“in‐kind” contributions by leveraging the talents of nearly 4,500 industry employee volunteers,
who have collectively volunteered almost 27,000 hours over the past five years. Other in‐kind
contributions include equipment donations and the use of company laboratory facilities,
particularly at the K‐12 levels, at a time when public school budgets are shrinking.
 A large majority (85%) of industry‐supported STEM education programs focus on the K‐12
levels and are aimed at improving the preparation of both students and teachers. This
suggests that PhRMA member companies are focused on systemic changes in the way STEM
education is taught in the U.S. by engaging younger students and early education teachers.
 Over 30 PhRMA member programs are focusing on increasing diversity in STEM fields by
providing students of all backgrounds, particularly women and minorities, experience with
hands‐on, inquiry‐based scientific learning opportunities.
At a time when other countries are devoting increasing funds and developing strategies to build a 21st
Century STEM workforce to attract R&D investment and the economic benefits it brings, the U.S. cannot
afford to continue to lag behind its global competitors. Improving STEM education in the U.S. is an
extensive and long‐term, but necessary undertaking that requires a multi‐stakeholder approach. This
report is intended to provide insights into the efforts of just one sector, the innovative
biopharmaceutical sector, in improving U.S. STEM education.